Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Angel Pharma to Start China Trial of ITK Inhibitor for Lymphoma

Angel Pharma, a Jiaxing- Los Angeles company, was approved to start China clinical trials of a small molecule ITK inhibitor in patients with relapsed/refractory T-cell lymphomas. CPI-818, the first ITK inhibitor in clinical development, is designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase) without affecting related kinases such as RLK and BTK. Corvus Pharma discovered the drug. One year ago, Corvus formed Angel as a China JV with $106 million in original capital and China rights to three of its assets, including CPI-818.  More details.... Stock Symbol: (NSDQ: CRVS) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.